News from noven pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 14, 2014, 09:00 ET
Sep 24, 2014, 13:00 ET

Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System)

 Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...

Mar 25, 2014, 09:00 ET
Noven Pharmaceuticals, Inc. (PRNewsFoto/Noven Pharmaceuticals, Inc.)

Noven Pharmaceuticals Announces Issuance of New U.S. Patent, an Important Addition to its Intellectual Property Portfolio for Brisdelle® (Paroxetine) Capsules, 7.5 mg

 Noven Pharmaceuticals, Inc. today announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,658,663, entitled "Method Of...

Jan 13, 2014, 09:00 ET
Noven Pharmaceuticals, Inc. (PRNewsFoto/Noven Pharmaceuticals, Inc.)

Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules

 Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Shionogi Inc. to co-promote Brisdelle™...

Nov 05, 2013, 09:00 ET
Brisdelle(TM) (Paroxetine) capsules Now Available by Prescription Nationwide.  (PRNewsFoto/Noven Pharmaceuticals, Inc.)

First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies

Noven Pharmaceuticals, Inc. today announced that Brisdelle™ (paroxetine) capsules, 7.5 mg, is now available by prescription nationwide....

Sep 18, 2013, 09:00 ET

Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with Menopause

 Noven Pharmaceuticals, Inc., today announced the publication of results from its two Phase 3 clinical studies in Menopause, the peer-reviewed,...

Jun 28, 2013, 17:26 ET
FDA approves Brisdelle(TM)(paroxetine) capsules, the first and only nonhormonal therapy for the treatment of moderate to severe vasomotor symptoms associated with menopause, commonly referred to as hot flashes and night sweats.  (PRNewsFoto/Noven Pharmaceuticals, Inc.)

Noven Receives FDA Approval for Brisdelle™ (Paroxetine) Capsules, the First Nonhormonal Therapy for Vasomotor Symptoms Associated with Menopause

 Noven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Brisdelle™ low-dose...

Mar 04, 2013, 18:20 ET

Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause

 Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...

Jan 29, 2013, 08:00 ET

Minivelle™ (Estradiol Transdermal System), The Smallest Estrogen Patch, Now Available in U.S. Pharmacies

Noven Pharmaceuticals, Inc., the manufacturer of Vivelle-Dot® (estradiol transdermal system), today announced the availability of...

Nov 12, 2012, 17:00 ET

FDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms

 Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application...

Oct 03, 2012, 00:01 ET

NOVEN ANNOUNCES POSITIVE PHASE 3 DATA RESULTS FOR INVESTIGATIONAL LOW-DOSE NONHORMONAL THERAPY FOR THE TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

 Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two...

Feb 26, 2004, 00:00 ET

Noven and Endo Announce Licensing Agreement for Fentanyl Patch

MIAMI and CHADDS FORD, Pa., Feb. 26 /PRNewswire-FirstCall/ -- Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) and Endo Pharmaceuticals Inc., a wholly...

Aug 18, 2000, 01:00 ET

Vivelle(R) (Estradiol Transdermal System) Receives Indication for Osteoporosis Prevention

MIAMI, Aug. 18 /PRNewswire/ -- Doctors now have a new, effective treatment option to help patients reduce their risk of developing...

Aug 17, 2000, 01:00 ET

Vivelle(R) (Estradiol Transdermal System) Receives Indication for Osteoporosis Prevention

MIAMI, Aug. 17 /PRNewswire/ -- Doctors now have a new, effective treatment option to help patients reduce their risk of developing...

Oct 16, 1997, 01:00 ET

Would You Rather Die Than Go To The Dentist? Survey Says You're Not Alone

WASHINGTON, D.C., Oct. 16 /PRNewswire/ -- It's a fact -- many Americans would rather "die" than go to the dentist. A recent study of dental...